Figure 4.

 Effects of dasatinib on the growth of gefitinib‐resistant non‐small cell lung cancer cells with MET amplification in vivo. Nude mice with tumor xenografts established by s.c. implantation of HCC827 GR5 cells were treated daily for 28 days with vehicle (control), gefitinib (50 mg/kg), or dasatinib (15 mg/kg) by oral gavage. Tumor volume was determined at the indicated times after the onset of treatment. Points indicate the mean of values from five mice per group; bars indicate SE. *P < 0.05 for dasatinib versus control or gefitinib alone (Student’s t‐test).